The rationale for the International Cooperative Growth Study, NutropinAq® European Registry (iNCGS) was to collect long-term data on effectiveness and safety using NutropinAq® under usual clinical conditions for the treatment of paediatric growth disorders for which GH is indicated. This evidence concerns the gene GH1 and hereditary endocrine growth disease.